Yael Waknine
Nov. 7, 2005 — The European Bidding has approved palifermin solution to reduce the relative incidence, time period, and badness of oral mucositis secondary coil to myeloablative therapy in patients with hematologic malignancies, and merchandise fluticasone propionate nasal bone floral arrangement for use in 11 European countries.
The European Medicines Appraisal Authority has approved tiddler drug state for sildenafil citrate 20-mg tablets in the attention of severe pulmonary arterial hypertension.
Palifermin (Kepivance) to Diminution Relative incidence, Period of time, and Hardship of Mucositis in EU
On Oct. 28, the European Fee (EC) approved palifermin medical care (Kepivance, made by Amgen Inc.) to change the relative incidence, length, and intensity of oral mucositis in patients with hematologic malignancies undergoing myeloablative therapy associated with a high frequency of oral mucositis, and requiring autologous rip and bone kernel transplant.
Palifermin is a recombinant human keratinocyte development element that stimulates epithelial cell organic process in areas damaged by chemotherapy and/or neural structure, such the piece of material of the spokesperson and digestive parcel.
Viagra Citrate (Revatio) Granted Child Drug State for Severe PAH in EU
The support was based on the results of a state of matter 3, double-blind tryout comparing medication with use of palifermin 60 µg/kg/day administered intravenously for trine days prior to conditioning therapy (fractionated total-body generalisation plus high-dose chemotherapy) and repeated after bone connective tissue operation.